6,910 Shares in Exelixis, Inc. (NASDAQ:EXEL) Purchased by Summit Trail Advisors LLC

Summit Trail Advisors LLC purchased a new stake in shares of Exelixis, Inc. (NASDAQ:EXEL) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 6,910 shares of the biotechnology company’s stock, valued at approximately $230,000.

Other institutional investors have also added to or reduced their stakes in the company. Sapient Capital LLC bought a new position in shares of Exelixis during the 4th quarter valued at approximately $256,000. Savant Capital LLC raised its stake in Exelixis by 1.2% during the fourth quarter. Savant Capital LLC now owns 70,831 shares of the biotechnology company’s stock valued at $2,359,000 after purchasing an additional 849 shares in the last quarter. Entropy Technologies LP raised its stake in Exelixis by 18.7% during the fourth quarter. Entropy Technologies LP now owns 21,731 shares of the biotechnology company’s stock valued at $724,000 after purchasing an additional 3,431 shares in the last quarter. Empowered Funds LLC bought a new position in Exelixis during the fourth quarter valued at $7,455,000. Finally, Paragon Capital Management Inc. purchased a new position in shares of Exelixis in the 4th quarter worth $1,642,000. Hedge funds and other institutional investors own 85.27% of the company’s stock.

Exelixis Stock Performance

Shares of NASDAQ:EXEL opened at $32.80 on Thursday. The firm’s 50 day simple moving average is $34.24 and its 200-day simple moving average is $30.72. Exelixis, Inc. has a one year low of $20.14 and a one year high of $37.59. The firm has a market cap of $9.37 billion, a PE ratio of 21.03, a price-to-earnings-growth ratio of 0.63 and a beta of 0.53.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings data on Tuesday, February 11th. The biotechnology company reported $0.48 EPS for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a return on equity of 20.99% and a net margin of 22.43%. Equities research analysts predict that Exelixis, Inc. will post 1.74 EPS for the current fiscal year.

Analysts Set New Price Targets

EXEL has been the topic of several recent research reports. Brookline Capital Management initiated coverage on shares of Exelixis in a research report on Monday, December 23rd. They set a “buy” rating on the stock. HC Wainwright restated a “buy” rating and set a $40.00 price objective on shares of Exelixis in a research report on Monday, January 27th. Truist Financial lifted their target price on Exelixis from $42.00 to $43.00 and gave the stock a “buy” rating in a report on Monday, January 27th. BMO Capital Markets lowered Exelixis from an “outperform” rating to a “market perform” rating and increased their price target for the company from $36.00 to $40.00 in a report on Friday, December 20th. Finally, Piper Sandler raised their price target on Exelixis from $37.00 to $38.00 and gave the stock an “overweight” rating in a research report on Wednesday. One research analyst has rated the stock with a sell rating, seven have given a hold rating and thirteen have assigned a buy rating to the company. According to MarketBeat.com, Exelixis has an average rating of “Moderate Buy” and an average target price of $37.00.

Insider Activity

In other news, EVP Jeffrey Hessekiel sold 60,000 shares of the company’s stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $36.67, for a total value of $2,200,200.00. Following the completion of the sale, the executive vice president now owns 486,059 shares of the company’s stock, valued at approximately $17,823,783.53. This represents a 10.99 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Patrick J. Haley sold 41,588 shares of Exelixis stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $34.36, for a total transaction of $1,428,963.68. Following the transaction, the executive vice president now directly owns 288,665 shares in the company, valued at approximately $9,918,529.40. The trade was a 12.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 111,588 shares of company stock worth $3,981,864. Company insiders own 2.85% of the company’s stock.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.